Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Bertelmann

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Acta Ophthalmologica|June 2, 2018
Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension studyNicolas Feltgen, Lars-Olof Hattenbach, Thomas Bertelmann, et al.
Plos One|May 16, 2014
Proteomics of vitreous humor of patients with exudative age-related macular degenerationMichael Janusz Koss, Janosch Hoffmann, Nauke Nguyen, et al.
Acta Ophthalmologica|March 3, 2017
Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)Lars-Olof Hattenbach, Nicolas Feltgen, Thomas Bertelmann, et al.
American Journal of Ophthalmology|July 13, 2016
ReplyHans Hoerauf, Nicolas Feltgen, Claudia Weiss, et al.
American Journal of Ophthalmology|May 11, 2016
Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label StudyHans Hoerauf, Nicolas Feltgen, Claudia Weiss, et al.
The British Journal of Ophthalmology|November 2, 2017
Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT studyChristoph Paul, Christine Heun, Hans-Helge Müller, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Acta Ophthalmologica|June 2, 2018
Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension studyNicolas Feltgen, Lars-Olof Hattenbach, Thomas Bertelmann, et al.
Plos One|May 16, 2014
Proteomics of vitreous humor of patients with exudative age-related macular degenerationMichael Janusz Koss, Janosch Hoffmann, Nauke Nguyen, et al.
Acta Ophthalmologica|March 3, 2017
Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)Lars-Olof Hattenbach, Nicolas Feltgen, Thomas Bertelmann, et al.
American Journal of Ophthalmology|July 13, 2016
ReplyHans Hoerauf, Nicolas Feltgen, Claudia Weiss, et al.
American Journal of Ophthalmology|May 11, 2016
Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label StudyHans Hoerauf, Nicolas Feltgen, Claudia Weiss, et al.
The British Journal of Ophthalmology|November 2, 2017
Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT studyChristoph Paul, Christine Heun, Hans-Helge Müller, et al.
Pageof 5